References 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, (1): p Keegan, T.H., et al., Compa

Size: px

Start display at page:

Download "References 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, (1): p Keegan, T.H., et al., Compa"

Imogen Lloyd
5 years ago
Views:

1 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, (1): p Keegan, T.H., et al., Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer, (7): p Alvarez, E., et al., Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers. Cancer, (13): p Hudson, M.M., et al., Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA, (22): p Chemaitilly, W., et al., Endocrine late effects in childhood cancer survivors. J Clin Oncol, 2018: p. JCO Faubion, S.S., C.L. Loprinzi, and K.J. Ruddy, Management of hormone deprivation symptoms after cancer. Mayo Clin Proc, (8): p Practice Committees of American Society for Reproductive, M. and T. Society for Assisted Reproductive, Mature oocyte cryopreservation: a guideline. Fertil Steril, (1): p

2 8. Oktay, K., et al., Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol, (19): p Djaladat, H., Organ sparing surgery for testicular tumours. Curr Opin Urol, (2): p Ntali, G. and N. Karavitaki, Efficacy and complications of pituitary irradiation. Endocrinol Metab Clin North Am, (1): p Meistrich, M.L., Effects of chemotherapy and radiotherapy on spermatogenesis in humans, in Fertil Steril p Howell, S.J. and S.M. Shalet, Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr, 2005(34): p Green, D.M., et al., Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol, (11): p Aldrink, J.H., et al., Using quality improvement methodology to improve ovarian salvage for benign ovarian masses. J Pediatr Surg, Luczak, J. and M. Baglaj, Selecting treatment method for ovarian masses in children 24 years of experience. J Ovarian Res, (1): p. 59.

3 16. Gershenson, D.M., Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol, : p Rosendahl, M., M.K. Simonsen, and J.J. Kjer, The influence of unilateral oophorectomy on the age of menopause. Climacteric, 2017: p Bjelland, E.K., et al., Is unilateral oophorectomy associated with age at menopause? A population study (the HUNT2 Survey). Hum Reprod, p dizerega, G.S., The peritoneum and its response to surgical injury. Prog Clin Biol Res, : p Practice Committee of the American Society for Reproductive Medicine. Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery. Fertil Steril, (1): p Meirow, D. and D. Nugent, The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update, (6): p Meirow, D., et al., Cortical fibrosis and blood vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod, (6): p Wallace, W.H., et al., Gonadal dysfunction due to cis platinum. Med Pediatr Oncol, (5): p

4 24. van Dorp, W., et al., Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: A report from the International Late effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. J Clin Oncol, (28): p Wallace, W.H., et al., Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys, (3): p Larsen, E.C., et al., Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. Acta Obstetricia Et Gynecologica Scandinavica, (1): p Green, D.M., et al., Fertility of female survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol, (16): p Green, D.M., et al., Quantifying alkylating agent exposure: Evaluation of the cyclophosphamide equivalent dose: A report from the Childhood Cancer Survivor Study. J Clin Oncol, (15). 29. Green, D.M., et al., The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report From the Childhood Cancer Survivor Study. Pediatr Blood Cancer, (1): p

5 30. Meirow, D., et al., Prevention of severe menorrhagia in oncology patients with treatment induced thrombocytopenia by luteinizing hormonereleasing hormone agonist and depo medroxyprogesterone acetate. Cancer, (7): p Eifel, P., et al., National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1 3, J Natl Cancer Inst, (13): p Goldhirsch, A., et al., Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol, (18): p Turner, N.H., et al., Utility of gonadotropin releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol, (9): p Del Mastro, L., et al., Gonadotropin releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in cancer women: systematic review and meta analysis of randomized trials. Cancer Treat Rev, (5): p

6 35. Oktay, K., et al., Absence of conclusive evidence for the safety and efficacy of gonadotropin releasing hormone analogue treatment in protecting against chemotherapy induced gonadal injury. Oncologist, (9): p Moore, H.C., et al., Goserelin for ovarian protection during breast cancer adjuvant chemotherapy. N Engl J Med, (10): p Hickman, L.C., et al., Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta analysis of the potential role for gonadotropin releasing hormone agonists. J Assist Reprod Genet, (4): p Lambertini, M., et al., Gonadotropin releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta analysis of individual patient level data. J Clin Oncol, (19): p Kano, M., et al., AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci U S A, (9): p. E1688 E1697.

7 40. Woodruff, T.K., A win win for womenʹs reproductive health: A nonsteroidal contraceptive and fertoprotective neoadjuvant. Proc Natl Acad Sci U S A, (9): p Gonfloni, S., et al., Inhibition of the c Abl TAp63 pathway protects mouse oocytes from chemotherapy induced death. Nat Med, (10): p Morgan, S., et al., Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. Plos One, (7). 43. Kerr, J.B., et al., Cisplatin induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat Med, (8): p ; author reply Cherry, S.M., P.A. Hunt, and T.J. Hassold, Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation. Mutat Res GenetToxicol Environ Mutagen, (2): p Woodruff, T.K., Preserving fertility during cancer treatment. Nat Med, (10): p Wang Rodriguez, J., et al., STI 571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope, (8): p Prockop, D.J., Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, (5309): p

Updated Analysis of Non-Surgical Premature Menopause in the Childhood Cancer Survivor Study

Analysis Concept Proposal 1. Study Title Updated Analysis of Non-Surgical Premature Menopause in the Childhood Cancer Survivor Study 2. Working Group and Investigators CCSS Working Group: Chronic Disease